The Obesity ETF (SLIM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026
Biohaven Ltd. is downgraded from Strong Buy to Hold following the FDA's Complete Response Letter for troriluzole in Spinocerebellar Ataxia. BHVN pivots focus to three late-stage programs: MODE/TRAP degraders [BHV-1400, BHV-1300], Kv7 activator Opakalim, and myostatin-activin inhibitor taldefgrobep alfa for obesity. Taldefgrobep alfa targets obesity with a novel MOA aiming for fat loss, muscle gain, and improved safety versus GLP-1s; phase 2 POC data is expected in 2H 2026.
Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety Moat
Structure Therapeutics (GPCR) is initiated with a BUY rating and $110 price target, reflecting a 101% upside from current levels. Aleniglipron, GPCR's oral GLP-1 agonist, demonstrated 16.3% placebo-adjusted weight loss at 44 weeks with superior safety and manufacturing cost advantages. GPCR's $1.4B cash position provides runway through 2028 and a valuation floor of $23.10 in a bear scenario.
How to Play Lilly Stock Post Oral Obesity Pill Foundayo's Approval
LLY wins FDA nod for oral obesity pill Foundayo, boosting shares as it eyes billions in sales and a fast catch-up to rivals in the booming GLP-1 market.
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight
Foundayo (orforglipron) has a serious advantage over Novo Nordisk's Wegovy pill. Retatrutide, a subcutaneous triple hormone receptor agonist in phase 3 trials, could be a game changer.
Wave Life Sciences Slips as Obesity Data Fails to Convince
Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets following updated Phase 1 INLIGHT trial data for WVE-007, the company's obesity candidate.
Novo Nordisk Says Experimental Diabetes and Obesity Drug Shows Positive Results
The drugmaker said UBT251 achieved mean body weight reduction of up to 9.8% after a 24-week trial.
Why Eli Lilly Remains My Top Obesity Bet
Despite HSBC downgrading Eli Lilly and Company stock, it remains my favorite in the obesity treatment market. That's also because LLY's tirzepatide franchise sales grew 114.6% year-on-year to about $11.7 billion in Q4. Meanwhile, on March 19, Eli Lilly published promising clinical data on retatrutide for the treatment of type 2 diabetes.
FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April 2026.
Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares
Eli Lilly (NYSE:LLY) stock is down 5% in Tuesday afternoon trading, with shares falling to $937 from a prior close of $989.12.
Eli Lilly Stock Downgraded on Inflated Obesity Drug Market
Eli Lilly And Co ( NYSE:LLY) stock is down 2.2% to trade at $967.06 at last glance, after a downgrade at HSBC "reduce" from "hold.
Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
Eli Lilly and Co (NYSE: LLY) on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitamin B12.
Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound
Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform. The post Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound appeared first on Investor's Business Daily.
